Q-omics provides the consensus-scored PXMP4 profile across patient tissues and cancer cell-line models. PXMP4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PXMP4 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, PXMP4 RNA expression shows 18,910 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, LUAD, and UVM as cancer lineages where PXMP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PXMP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PXMP4 survival associations across molecular data types. PXMP4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PXMP4 RNA expression–survival associations across cancer types. High PXMP4 expression shows unfavorable associations in MESO, but favorable associations in KIRP, KIRC, LUAD, READ and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PXMP4 RNA expression.
This table summarizes PXMP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PXMP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PXMP4 shows lower tumor expression in LUAD, THCA, KIRC and LUSC and higher tumor expression in LIHC and STAD. The LUAD box plot shows higher PXMP4 RNA expression in normal versus tumor tissue (log2 FC = −1.596, t-test p < 0.001).
This table shows molecular features associated with PXMP4 in patient tissues and cancer cell lines. In patient samples, PXMP4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PXMP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and STOMACH.
